Advertisement

Allergan: AbbVie’s expensive facelift

Pharma giant AbbVie is buying Botox maker Allergan for $63bn. That’s a huge sum given the target’s uncertain prospects. Matthew Partridge reports.

Woman getting botox injection in her face.
Botox is facing stiff competition

Yet another "pharmaceutical behemoth" looks set to emerge, says Chris Isidore on CNN. AbbVie (NYSE: ABBV) has announced that it will buy Allergan (NYSE: AGN) for $63bn. The latter's shares jumped nearly 30% on the news. Takeover activity in the sector has intensified recently, with Pfizer announcing an $1bn takeover of Array a few days ago.Earlier this year, Bristol-Myers Squibb offered $74bn for Celgene, though that deal has yet to be approved.

Advertisement - Article continues below

There is strategic logic to the deal, says The Wall Street Journal. Buying Allergan would allow AbbVie to dominate the $8bn-plus market for Botox and other beauty drugs, along with several "popular eye treatments". Along with "some overlap in treatments for brain, women's health, stomach and other disorders", the combination "would take AbbVie into the new realm of frown-line smoothing, eyelash lengthening and double-chin removal". What's more, Allergan's nearly $16bn in yearly revenue "would also give AbbVie another source of cash to hunt for a new generation of products".

Propping up the pipeline

If AbbVie assumes that buying Allergan will help it improve its pipeline, it should think again, says Max Nisen on Bloomberg. Allergan is notorious for its "ageing products, questionable deals, and research failures", which have prompted Allergan's own investors to call "for a breakup of the company or a change in management". For instance, despite Botox's "impressive brand recognition and a solid grip on the market", its long-term potential is uncertain owing to new drugs from competing firms, which aim to tackle both wrinkles and migraines (the other medical use for Botox).

Not only does Allergan fail to provide more than "a temporary facelift" but the 45% premium to the current price makes it "excessively expensive", says Robert Cyran for Breaking Views.

Even if the deal delivers the projected annual savings of $2bn, this still doesn't justify the $20bn cost of the transaction, not to mention the "hefty" $60bn in assumed and newly raised debt. Given the fact that Big Pharma "has a miserable track record delivering value from large deals", it's no surprise that the announcement of the deal has wiped $15bn off AbbVie's market value.

Advertisement
Advertisement

Recommended

The British equity market is shrinking
Stockmarkets

The British equity market is shrinking

British startups are abandoning public stockmarkets and turning to deep-pocketed Silicon Valley venture capitalists for their investment needs.
8 Nov 2019
Should Big Tech be broken up?
Tech stocks

Should Big Tech be broken up?

The dominance of the big four technology giants has attracted the attention of politicians determined to humble them. But what real harm are they doin…
8 Aug 2020
Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
7 Aug 2020
BP has slashed its dividend – and markets love it
Income investing

BP has slashed its dividend – and markets love it

BP has bowed to the inevitable and cut its dividend in half – and its share price promptly rose. John Stepek explains what it means for shareholders …
4 Aug 2020

Most Popular

Eagle Lightweight GT: the reincarnation of the E-type Jag
Toys and gadgets

Eagle Lightweight GT: the reincarnation of the E-type Jag

Jaguar’s classic E-type sports car has been reinvented for the modern age. The result – the Eagle Lightweight GT – is a thing of beauty.
7 Aug 2020
Platinum: the precious metal that looks set to play catch-up with silver and gold
Silver and other precious metals

Platinum: the precious metal that looks set to play catch-up with silver and gold

Gold and silver continue to soar, but there's still time to get in. And there's another precious metal that looks set to go on a bull run too, says Jo…
7 Aug 2020
Don’t despair on dividends – these companies could be set to bring them back
Income investing

Don’t despair on dividends – these companies could be set to bring them back

The value of dividends paid out by UK stocks has plummeted this year as companies “rebase” their payment policies. But things could soon start to look…
6 Aug 2020